{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:12:32Z","timestamp":1781835152229,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Senju Pharmaceutical Co., Ltd."},{"DOI":"10.13039\/501100005611","name":"University of Fukui","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005611","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s12325-023-02589-9","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T04:01:36Z","timestamp":1689393696000},"page":"4074-4092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine\/0.5% Timolol Versus 1% Dorzolamide\/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0896-996X","authenticated-orcid":false,"given":"Masaru","family":"Inatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Orii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Arimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Sunagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Shiokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Sakono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takato","family":"Sakono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Kuwamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Oi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Kuwayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineo","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuru","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Musashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyasu","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Nakakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyasu","family":"Sameshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Urahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumika","family":"Watanabe-Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumie","family":"Kagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Kurimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Yamada-Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosuke","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aika","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Tanito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"key":"2589_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ophtha.2015.10.053","volume":"123","author":"BE Prum Jr","year":"2016","unstructured":"Prum BE Jr, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, et al. Primary open-angle glaucoma preferred practice pattern\u00ae guidelines. Ophthalmology. 2016;123:41\u2013111. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.053.","journal-title":"Ophthalmology"},{"key":"2589_CR2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","volume":"385","author":"DF Garway-Heath","year":"2015","unstructured":"Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295\u2013304. https:\/\/doi.org\/10.1016\/S0140-6736(14)62111-5.","journal-title":"Lancet"},{"key":"2589_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487\u201397. https:\/\/doi.org\/10.1056\/NEJMra050100.","journal-title":"N Engl J Med"},{"key":"2589_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10384-021-00844-6","volume":"65","author":"M Aihara","year":"2021","unstructured":"Aihara M. Prostanoid receptor agonists for glaucoma treatment. Jpn J Ophthalmol. 2021;65:581\u201390. https:\/\/doi.org\/10.1007\/s10384-021-00844-6.","journal-title":"Jpn J Ophthalmol"},{"issue":"Suppl1","key":"2589_CR5","first-page":"1","volume":"105","author":"European Glaucoma Society","year":"2021","unstructured":"European Glaucoma Society. European glaucoma society terminology and guidelines for glaucoma. 5th ed. Br J Ophthalmol. 2021;105(Suppl1):1\u2013169.","journal-title":"Br J Ophthalmol."},{"key":"2589_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1517\/14656561003667540","volume":"11","author":"MR Razeghinejad","year":"2010","unstructured":"Razeghinejad MR, Sawchyn AK, Katz LJ. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma. Expert Opin Pharmacother. 2010;11:959\u201368. https:\/\/doi.org\/10.1517\/14656561003667540.","journal-title":"Expert Opin Pharmacother"},{"key":"2589_CR7","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1517\/14656566.2014.936850","volume":"15","author":"G Holl\u00f3","year":"2014","unstructured":"Holl\u00f3 G, Topouzis F, Fechtner RD. Fixed combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15:1737\u201347. https:\/\/doi.org\/10.1517\/14656566.2014.936850.","journal-title":"Expert Opin Pharmacother"},{"key":"2589_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12325-020-01525-5","volume":"38","author":"AG Konstas","year":"2021","unstructured":"Konstas AG, Schmetterer L, Katsanos A, Hutnik CML, Holl\u00f3 G, Quaranta L, et al. Dorzolamide\/timolol fixed combination: learning from the past and looking toward the future. Adv Ther. 2021;38:24\u201351. https:\/\/doi.org\/10.1007\/s12325-020-01525-5.","journal-title":"Adv Ther"},{"key":"2589_CR9","doi-asserted-by":"publisher","first-page":"e0146680","DOI":"10.1371\/journal.pone.0146680","volume":"11","author":"NY Lee","year":"2016","unstructured":"Lee NY, Park HY, Park CK. Comparison of the effects of dorzolamide\/timolol fixed combination versus latanoprost on intraocular pressure and ocular perfusion pressure in patients with normal-tension glaucoma: a randomized crossover clinical trial. PLOS ONE. 2016;11:e0146680. https:\/\/doi.org\/10.1371\/journal.pone.0146680.","journal-title":"PLOS ONE"},{"key":"2589_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/IJG.0b013e3181b4cab4","volume":"19","author":"M Hatanaka","year":"2010","unstructured":"Hatanaka M, Reis A, Sano ME, Susanna R Jr. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%\/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. J Glaucoma. 2010;19:331\u20135. https:\/\/doi.org\/10.1097\/IJG.0b013e3181b4cab4.","journal-title":"J Glaucoma"},{"key":"2589_CR11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1345\/aph.1K565","volume":"42","author":"MR Lesk","year":"2008","unstructured":"Lesk MR, Koulis T, Sampalis F, Sampalis JS, Bastien NR. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Ann Pharmacother. 2008;42:498\u2013504. https:\/\/doi.org\/10.1345\/aph.1K565.","journal-title":"Ann Pharmacother"},{"key":"2589_CR12","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1185\/03007995.2011.613923","volume":"27","author":"F Aptel","year":"2011","unstructured":"Aptel F, Denis P. Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Curr Med Res Opin. 2011;27:1949\u201358. https:\/\/doi.org\/10.1185\/03007995.2011.613923.","journal-title":"Curr Med Res Opin"},{"key":"2589_CR13","doi-asserted-by":"publisher","first-page":"e83606","DOI":"10.1371\/journal.pone.0083606","volume":"8","author":"M He","year":"2013","unstructured":"He M, Wang W, Huang W. Efficacy and tolerability of the fixed combinations latanoprost\/timolol versus dorzolamide\/timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials. PLOS ONE. 2013;8:e83606. https:\/\/doi.org\/10.1371\/journal.pone.0083606.","journal-title":"PLOS ONE."},{"key":"2589_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/OPTH.S38575","volume":"7","author":"A Sanseau","year":"2013","unstructured":"Sanseau A, Sampaolesi J, Suzuki ER Jr, Lopes JF, Borel H. Preference for a fixed combination of brinzolamide\/timolol versus dorzolamide\/timolol among patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:357\u201362. https:\/\/doi.org\/10.2147\/OPTH.S38575.","journal-title":"Clin Ophthalmol"},{"key":"2589_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/00061198-200310000-00001","volume":"12","author":"JC Tsai","year":"2003","unstructured":"Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393\u20138. https:\/\/doi.org\/10.1097\/00061198-200310000-00001.","journal-title":"J Glaucoma"},{"key":"2589_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.clinthera.2006.04.007","volume":"28","author":"R Reis","year":"2006","unstructured":"Reis R, Queiroz CF, Santos LC, Avila MP, Magacho L. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28:552\u20139. https:\/\/doi.org\/10.1016\/j.clinthera.2006.04.007.","journal-title":"Clin Ther."},{"key":"2589_CR17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1089\/jop.2012.0195","volume":"29","author":"AG Konstas","year":"2013","unstructured":"Konstas AG, Holl\u00f3 G, Haidich AB, Mikropoulos DG, Giannopoulos T, Voudouragkaki IC, et al. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide\/timolol or brimonidine\/timolol fixed combination adjunctive to travoprost therapy. J Ocul Pharmacol Ther. 2013;29:652\u20137. https:\/\/doi.org\/10.1089\/jop.2012.0195.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2589_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1185\/03007995.2012.665363","volume":"28","author":"JW Cheng","year":"2012","unstructured":"Cheng JW, Cheng SW, Yu DY, Wei RL, Lu GC. Meta-analysis of \u03b12-adrenergic agonists versus carbonic anhydrase inhibitors as adjunctive therapy. Curr Med Res Opin. 2012;28:543\u201350. https:\/\/doi.org\/10.1185\/03007995.2012.665363.","journal-title":"Curr Med Res Opin"},{"key":"2589_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","volume":"123","author":"T Li","year":"2016","unstructured":"Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123:129\u201340. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.005.","journal-title":"Ophthalmology"},{"key":"2589_CR20","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1185\/03007995.2010.482017","volume":"26","author":"J Garc\u00eda-Feijo\u00f3","year":"2010","unstructured":"Garc\u00eda-Feijo\u00f3 J, S\u00e1enz-Franc\u00e9s F, Mart\u00ednez-de-la-Casa JM, M\u00e9ndez-Hern\u00e1ndez C, Fern\u00e1ndez-Vidal A, Calvo-Gonz\u00e1lez C, et al. Comparison of ocular hypotensive actions of fixed combinations of brimonidine\/timolol and dorzolamide\/timolol. Curr Med Res Opin. 2010;26:1599\u2013606. https:\/\/doi.org\/10.1185\/03007995.2010.482017.","journal-title":"Curr Med Res Opin"},{"key":"2589_CR21","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1185\/03007990902994041","volume":"25","author":"DR Nixon","year":"2009","unstructured":"Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S, Hollander DA. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed combination therapy. Curr Med Res Opin. 2009;25:1645\u201353. https:\/\/doi.org\/10.1185\/03007990902994041.","journal-title":"Curr Med Res Opin"},{"key":"2589_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10792-011-9495-z","volume":"31","author":"G Gulkilik","year":"2011","unstructured":"Gulkilik G, Oba E, Odabas\u0131 M. Comparison of fixed combinations of dorzolamide\/timolol and brimonidine\/timolol in patients with primary open-angle glaucoma. Int Ophthalmol. 2011;31:447\u201351. https:\/\/doi.org\/10.1007\/s10792-011-9495-z.","journal-title":"Int Ophthalmol"},{"key":"2589_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1185\/030079907x178694","volume":"23","author":"ES Arcieri","year":"2007","unstructured":"Arcieri ES, Arcieri RS, Pereira AC, Andreo EG, Finotti IG, S\u00e1 Filho WF. Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. Curr Med Res Opin. 2007;23:683\u20139. https:\/\/doi.org\/10.1185\/030079907x178694.","journal-title":"Curr Med Res Opin"},{"key":"2589_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/IJG.0b013e318168f008","volume":"17","author":"M Hatanaka","year":"2008","unstructured":"Hatanaka M, Grigera DE, Barbosa WL, Jordao M, Susanna R Jr. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%\/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%\/dorzolamide 2% in patients with elevated intraocular pressure. J Glaucoma. 2008;17:674\u20139. https:\/\/doi.org\/10.1097\/IJG.0b013e318168f008.","journal-title":"J Glaucoma."},{"key":"2589_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3109\/02713683.2011.584651","volume":"36","author":"N Y\u00fcksel","year":"2011","unstructured":"Y\u00fcksel N, G\u00f6k M, Alt\u0131nta\u015f O, Ca\u011flar Y. Diurnal intraocular pressure efficacy of the timolol-brimonidine fixed combination and the timolol-dorzolamide fixed combination as a first choice therapy in patients with pseudoexfoliation glaucoma. Curr Eye Res. 2011;36:804\u20138. https:\/\/doi.org\/10.3109\/02713683.2011.584651.","journal-title":"Curr Eye Res"},{"key":"2589_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/eye.2011.239","volume":"26","author":"AG Konstas","year":"2012","unstructured":"Konstas AG, Quaranta L, Yan DB, Mikropoulos DG, Riva I, Gill NK, et al. Twenty-four hour efficacy with the dorzolamide\/timolol-fixed combination compared with the brimonidine\/timolol-fixed combination in primary open-angle glaucoma. Eye (Lond). 2012;26:80\u20137. https:\/\/doi.org\/10.1038\/eye.2011.239.","journal-title":"Eye (Lond)"},{"key":"2589_CR27","first-page":"336","volume":"37","author":"M Araie","year":"2020","unstructured":"Araie M, Fukuchi T, Nakamura M, Sekiya T. Phase III study to evaluate the efficacy and safety of novel brimonidine\/timolol ophthalmic solution compared with timolol ophthalmic solution in patients with primary open-angle glaucoma (broad definition) or ocular hypertension. J Eye. 2020;37:336\u201344.","journal-title":"J Eye"},{"key":"2589_CR28","first-page":"345","volume":"37","author":"M Araie","year":"2020","unstructured":"Araie M, Fukuchi T, Nakamura M, Sekiya T. Long-term efficacy and safety of novel brimonidine\/timolol ophthalmic solution in patients with primary open-angle glaucoma (broad definition) or ocular hypertension. J Eye. 2020;37:345\u201352.","journal-title":"J Eye"},{"key":"2589_CR29","first-page":"37","volume":"63","author":"M Isobe","year":"2014","unstructured":"Isobe M, Koizumi K, Tsuji T, Imai K, Bahadursingh K, Hara M. Dorzolamide hydrochloride\/timolol maleate special survey of COSOPT ophthalmic solution. J New Rem Clin. 2014;63:37\u201369.","journal-title":"J New Rem Clin"},{"key":"2589_CR30","first-page":"495","volume":"115","author":"Y Kitazawa","year":"2011","unstructured":"Kitazawa Y, Araie M, Research Group on MK-0507A. Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride\/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension. J Jpn Ophthalmol Soc. 2011;115:495\u2013507.","journal-title":"J Jpn Ophthalmol Soc"},{"key":"2589_CR31","unstructured":"Senju Pharmaceutical Co., Ltd. Aibeta combination ophthalmic solution common technical document. https:\/\/www.pmda.go.jp\/drugs\/2019\/P20191001001\/index.html. Accessed May 16 2023."},{"key":"2589_CR32","first-page":"1341","volume":"37","author":"S Ohno","year":"2001","unstructured":"Ohno S, Uchio E, Ishizaki M, Takamura E, Ebihara N, Shoji J, et al. New clinical evaluation standard and seriousness classification of allergic conjunctival diseases. Med Drug J. 2001;37:1341\u20139.","journal-title":"Med Drug J"},{"key":"2589_CR33","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archopht.121.11.1537","volume":"121","author":"K Miyata","year":"2003","unstructured":"Miyata K, Amano S, Sawa M, Nishida T. A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch Ophthalmol. 2003;121:1537\u20139. https:\/\/doi.org\/10.1001\/archopht.121.11.1537.","journal-title":"Arch Ophthalmol"},{"key":"2589_CR34","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ophtha.2009.01.036","volume":"116","author":"JW Cheng","year":"2009","unstructured":"Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009;116:1243\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2009.01.036.","journal-title":"Ophthalmology"},{"issue":"1","key":"2589_CR35","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.12829","volume":"94","author":"H Tanihara","year":"2016","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Fukushima A, et al. One-year clin eval of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94(1):e26\u201334. https:\/\/doi.org\/10.1111\/aos.12829.","journal-title":"Acta Ophthalmol."},{"key":"2589_CR36","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1136\/bjo.82.11.1285","volume":"82","author":"T Shafi","year":"1998","unstructured":"Shafi T, Koay P. Randomised prospective masked study comparing patient comfort following the instillation of topical Proxymetacaine and amethocaine. Br J Ophthalmol. 1998;82:1285\u20137. https:\/\/doi.org\/10.1136\/bjo.82.11.1285.","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 2","key":"2589_CR37","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1016\/s0039-6257(99)00111-3","volume":"44","author":"LH Silver","year":"2000","unstructured":"Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide comfort study group. Surv Ophthalmol. 2000;44(Suppl 2):S141-5. https:\/\/doi.org\/10.1016\/s0039-6257(99)00111-3.","journal-title":"Surv Ophthalmol."},{"key":"2589_CR38","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1089\/jop.2006.0131","volume":"23","author":"K Chan","year":"2007","unstructured":"Chan K, Testa M, McCluskey P. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%\/timolol 0.5% compared with dorzolamide 2%\/timolol 0.5%. J Ocul Pharmacol Ther. 2007;23:372\u20136. https:\/\/doi.org\/10.1089\/jop.2006.0131.","journal-title":"J Ocul Pharmacol Ther."},{"key":"2589_CR39","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/IJG.0000000000001943","volume":"30","author":"YH Shu","year":"2021","unstructured":"Shu YH, Wu J, Luong T, Mattox C, Fang EN, Lee BL, et al. Topical medication adherence and visual field progression in open-angle glaucoma: analysis of a Large US health care system. J Glaucoma. 2021;30:1047\u201355. https:\/\/doi.org\/10.1097\/IJG.0000000000001943.","journal-title":"J Glaucoma"},{"key":"2589_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/s0002-9394(98)00286-4","volume":"127","author":"LJ Katz","year":"1999","unstructured":"Katz LJ. Brimonidine tartrate 0.2% twice daily vs. timolol 0.5% twice daily: 1-year results in glaucoma patients Brimonidine study group. Am J Ophthalmol. 1999;127:20\u20136. https:\/\/doi.org\/10.1016\/s0002-9394(98)00286-4.","journal-title":"Am J Ophthalmol."},{"key":"2589_CR41","doi-asserted-by":"publisher","first-page":"e26724","DOI":"10.1097\/MD.0000000000026724","volume":"100","author":"PH Yeh","year":"2021","unstructured":"Yeh PH, Cheng YC, Shie SS, Lee YS, Shen SC, Chen HS, et al. Brimonidine related acute follicular conjunctivitis: onset time and clinical presentations, a long-term follow-up. Medicine (Baltimore). 2021;100:e26724. https:\/\/doi.org\/10.1097\/MD.0000000000026724.","journal-title":"Medicine (Baltimore)."},{"key":"2589_CR42","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","volume":"124","author":"MB Sherwood","year":"2006","unstructured":"Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs. monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124:1230\u20138. https:\/\/doi.org\/10.1001\/archopht.124.9.1230.","journal-title":"Arch Ophthalmol."},{"key":"2589_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/jop.2005.21.337","volume":"21","author":"ER Craven","year":"2005","unstructured":"Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R, et al. Brimonidine and timolol fixed combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005;21:337\u201348. https:\/\/doi.org\/10.1089\/jop.2005.21.337.","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02589-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02589-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02589-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:20:11Z","timestamp":1692112811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02589-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2589"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02589-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]},"assertion":[{"value":"16 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}